ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,246Medicare Part D Prescriptions Filled, Including Refills

Rank: 38 out of 262

$447K Total Retail Price of All Prescriptions

Rank: 34 out of 262

422 Patients Receiving at Least One Drug in Part D
82%Patients 65 Years and Older
39% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in North Dakota
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 422 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

7% of this provider’s 422 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

1% of this provider’s 7,068 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

27% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$54 was the average price of a prescription from this provider, compared to $50 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in North Dakota
LEVOTHYROXINE SODIUM 462 442 1 2
SIMVASTATIN 291 260 2 1
FUROSEMIDE 241 231 3 4
HYDROCHLOROTHIAZIDE 182 168 4 7
LISINOPRIL 176 140 5 3
METOPROLOL SUCCINATE 164 149 6 11
FOSINOPRIL SODIUM 156 123 7 152
METOPROLOL TARTRATE 151 147 8 8
GLIMEPIRIDE 134 122 9 45
LISINOPRIL-HYDROCHLOROTHIAZIDE 132 104 10 24
POTASSIUM CHLORIDE 130 127 11 10
SERTRALINE HCL 122 94 12 14
AMLODIPINE BESYLATE 121 120 13 6
DONEPEZIL HCL 114 114 14 23
OMEPRAZOLE 109 91 15 5
ALLOPURINOL 108 88 16 22
METFORMIN HCL 102 96 17 9
ATORVASTATIN CALCIUM 93 93 18 13
HYDROCODONE-ACETAMINOPHEN 92 75 S3 19 15
WARFARIN SODIUM 88 88 20 12
TAMSULOSIN HCL 85 78 21 25
TRAZODONE HCL 80 75 22 36
METFORMIN HCL ER 77 62 23 63
ATENOLOL 74 59 24 16
CRESTOR 74 73 24 30
TRAMADOL HCL 69 67 26 18
DOXAZOSIN MESYLATE 69 69 26 59
GABAPENTIN 68 51 28 19
LANTUS SOLOSTAR 67 61 29 49
ZETIA 66 46 30 60
CARVEDILOL 66 66 30 31
VERAPAMIL ER 63 58 32 94
DILTIAZEM ER 63 63 32 75
NIFEDIPINE ER 63 63 32 194
SULFAMETHOXAZOLE-TRIMETHOPRIM 62 53 35 93
ZOLPIDEM TARTRATE 60 48 36 26
BENICAR 59 59 37 148
NOVOLOG FLEXPEN 57 33 38 97
DIGOXIN 52 52 39 28
VENLAFAXINE HCL ER 52 15 39 79
TRIAMTERENE-HCTZ 52 43 39 32
CYMBALTA 52 49 39 67
CITALOPRAM HBR 51 50 43 20
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 8, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.